Related Experiment Video
Updated: Sep 9, 2025
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Improving immune-related health outcomes post-cesarean birth with a gut microbiome-based program: A randomized
Pamela A Nieto1, Claudia Nakama1, Julian Trachsel1
1Seeding Inc, Doing Business as Tiny Health, Austin, Texas, USA.
Insights
A personalized microbiome program improved the gut microbiome in infants born via Cesarean section. This intervention reduced the risk of atopic dermatitis, promoting healthier immune development.
Area of Science:
- Microbiome research
- Pediatric health
- Immunology
Background:
- Infants born via Cesarean section (C-section) exhibit distinct gut microbiome profiles and increased risks for atopic and immune-related conditions compared to vaginally delivered infants.
- Cesarean delivery is associated with altered gut microbial colonization, potentially impacting long-term immune system development.
Purpose of the Study:
- To evaluate the efficacy of a microbiome-based program in modulating the gut microbiome of C-section born infants.
- To assess the impact of the intervention on microbiome composition, a C-section index, and the prevalence of atopic conditions.
Main Methods:
- An open-label, randomized controlled trial involving 54 full-term C-section born infants (0-3 months).
- The intervention group (n=25) received microbiome reports, personalized recommendations, educational materials, and coaching for 6 months.
- The control group (n=29) received standard care. Health conditions were monitored via parental surveys.
Main Results:
- The intervention group showed increased Bifidobacterium abundance and enhanced human milk oligosaccharide degradation gene activity compared to controls.
- The C-section index in the intervention arm decreased to levels comparable to vaginally born infants.
- Atopic dermatitis prevalence was significantly lower in the intervention arm (OR, 0.17; P=.031).
Conclusions:
- A personalized, microbiome-focused intervention can effectively modulate the gut microbiome in infants born via C-section.
- This program shows potential in reducing the incidence of atopic conditions in this vulnerable population.
- Findings support the use of microbiome-based strategies to mitigate C-section-associated health risks.
Background:
Infants born via Cesarean section (C-section) often have a distinct gut microbiome and higher risks of atopic and immune-related conditions than vaginally delivered infants. We evaluated whether a microbiome-based program could shift gut microbiome composition and improve microbiome-associated health outcomes in C-section born infants.
Methods:
This open-label, randomized, controlled trial included full-term C-section-born infants aged 0-3 months, randomized to an intervention (n = 25) or control arm (n = 29). Over 6 months, the intervention arm received two microbiome reports, personalized recommendations based on their microbiome, educational materials, and coaching calls focused on microbiome health. Parents reported health conditions via surveys.
Primary Outcome:
Difference between study arms in relative abundance of key gut microbiome taxa and functional genes. Other outcomes: Changes in a C-section index-a taxonomy-based metric comparing C-section-associated taxa to vaginally-associated taxa-and prevalence of atopic conditions.
Results:
Compared to controls, the intervention arm had higher Bifidobacterium (p = .025, q = .121) and higher abundance of genes associated with human milk oligosaccharide degradation (e.g., α-L-fucosidase, p = .019, q = .046) at timepoint 2. In the intervention arm, the C-section index decreased to a level similar to vaginally born infants (p = .807, q = .807). At the end of the intervention, atopic dermatitis prevalence was lower in the intervention arm than in controls (odds ratio, 0.17 [95% CI, 0.023-0.723], p = .031).
Conclusion:
A personalized microbiome-based program can modulate the gut microbiome of C-section-born infants and may reduce the risk of atopic conditions (ClinicalTrials.gov: NCT06424691).
Related Concept Videos
01:23Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...